What occurred
Shares of Viatris (VTRS -0.67%) fell 24.4% in February, based on information supplied by S&P International Market Intelligence. The inventory has since fallen even additional.
So what
The healthcare inventory’s huge drop on Feb. 28 got here after the corporate introduced in its fourth-quarter earnings report that it was promoting its biosimilars portfolio to Biocon Biologics, a privately held firm in India, for as much as $3.335 billion. Buyers did not just like the transfer as a result of it took out a possible driver of revenue. The corporate stated it made the transfer to concentrate on a few of its early-stage therapies.
Picture supply: Getty Pictures.
Viatris, fashioned by the merger of the Upjohn generic drug division of Pfizer with generic-drug maker Mylan, misplaced cash in its first full yr as an organization.
Viatris reported a web lack of $263.8 million within the fourth quarter, a per-share lack of $0.22. The corporate grew income within the quarter to $4.331 billion, up 21% yr over yr. For the total yr, it reported income of $17.8 billion, down 3% on an operational foundation, and it had a loss for the yr of $1.269 billion, in comparison with a lack of $699.9 million final yr.
It additionally did not assist allay considerations when it predicted that 2022 income will decline to a variety of $17 billion to $17.5 billion.
Now what
Some traders would possibly take a look at the inventory’s dip as a chance, regardless of its losses. The corporate presents a quarterly dividend that simply elevated by 9%, for a yield of 4.48%. And the payout seems to be effectively lined with a payout ratio of 15.91%.
Its low price-to-sales ratio of 0.678 makes it a cut price, particularly contemplating that the corporate solely wants to chop prices to turn out to be worthwhile. Income ought to improve as soon as it launches generics for blood-clot preventers Xarelto and Eliquis, which had $12.6 billion and $20.2 billion in worldwide gross sales final yr, respectively, and for Revlimid, which slows tumor development and had $6.6 billion in gross sales final yr.
